Marshall Wace LLP Grows Position in NewAmsterdam Pharma (NASDAQ:NAMS)

Marshall Wace LLP grew its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 161.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 288,446 shares of the company's stock after purchasing an additional 178,322 shares during the quarter. Marshall Wace LLP owned approximately 0.31% of NewAmsterdam Pharma worth $7,413,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Jennison Associates LLC increased its holdings in shares of NewAmsterdam Pharma by 291.9% during the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock valued at $102,763,000 after purchasing an additional 2,978,263 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of NewAmsterdam Pharma by 2,410.4% during the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock valued at $59,499,000 after purchasing an additional 2,222,900 shares in the last quarter. Alliancebernstein L.P. purchased a new position in shares of NewAmsterdam Pharma during the 4th quarter valued at approximately $47,752,000. Pictet Asset Management Holding SA raised its position in NewAmsterdam Pharma by 13.8% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,157,452 shares of the company's stock worth $29,747,000 after acquiring an additional 140,605 shares during the period. Finally, TimesSquare Capital Management LLC raised its position in shares of NewAmsterdam Pharma by 250.9% during the 4th quarter. TimesSquare Capital Management LLC now owns 895,574 shares of the company's stock worth $23,016,000 after purchasing an additional 640,329 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, March 3rd. Needham & Company LLC reiterated a "buy" rating and issued a $42.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Scotiabank increased their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a report on Thursday, February 27th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $43.33.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares of the company's stock, valued at approximately $305,550. The trade was a 90.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James N. Topper acquired 4,005 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average cost of $21.02 per share, with a total value of $84,185.10. Following the completion of the transaction, the director now owns 3,012,434 shares in the company, valued at approximately $63,321,362.68. The trade was a 0.13 % increase in their position. The disclosure for this purchase can be found here. 19.50% of the stock is currently owned by corporate insiders.

NewAmsterdam Pharma Stock Up 1.8 %

NAMS stock traded up $0.31 during midday trading on Monday, hitting $17.83. The company's stock had a trading volume of 357,200 shares, compared to its average volume of 593,679. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $27.29. The firm has a market capitalization of $1.96 billion, a P/E ratio of -6.86 and a beta of -0.01. The firm has a 50-day simple moving average of $19.58 and a 200-day simple moving average of $21.24.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. On average, sell-side analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.